all report title image

Anti-malarial Drugs Market, By Drug Class (Aminoquinolines, Quinoline-methanol (4-quinolinemethanols), Cinchona Alkaloids, Biguanides, Sulfonamides and Sulfones, and Others), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

  • Published In : Jun 2023
  • Code : CMI3726
  • Pages :162
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical
Ingographics Image

Plasmodium parasites, a protozoan parasite, are the cause of the widespread infectious disease malaria. A parasite enters the body through the bite of an infected female Anopheles mosquito, which then travels to the liver, where the parasite is produced. Human malaria are generally caused by five types of plasmodium parasites, including P. falciparum, P. malariae, P. ovale, P. vivax, and P.knowlesi. The most dangerous parasite species among these are P. falciparum and P. vivax, which are also the ones responsible for the majority of malaria deaths. Antimalarial drugs are used for the treatment and prevention of malaria infection. Most antimalarial drugs target the erythrocytic stage of malaria infection, which is the phase of infection that causes symptomatic illness. Early diagnosis and efficient treatment are crucial measures to control malaria. Different types of drugs such as quinine, chloroquine, mefloquine, proguanil, primaquine, and others are used in the treatment of malaria. Moreover, some combination drugs such as Pyrimethamine & sulfadoxine, Artemether & lumefantrine, and others are also prescribed for treating the disease.

Market Dynamics

The ongoing research and development for malarial treatment is expected to fuel growth of the market in the forecast period. Various drugs are undergoing the clinical trial for the malarial treatment, which is also expected to drive the market during the forecast period. Moreover, various pharmaceutical companies are actively participating in research and development activities, in order to develop novel drug entity for treatment of malaria. For instance, in November 2022, Novartis AG, a multinational pharmaceutical corporation and Medicines for Malaria Venture (MMV), a product development partnership in the field of antimalarial drug research and development announced decision to move to Phase 3 study for novel non-artemisinin combination to treat uncomplicated malaria. This novel combination also contains an optimized formulation of lumefantrine, which allows it to be given once daily versus the usual twice-daily administration. As the world faces emerging resistance to current malaria treatments, new medicines are needed to continue the fight toward elimination.

Key features of the study:

  • This report provides in-depth analysis of the global anti-malarial drugs market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global anti-malarial drugs market based on the following parameters–company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study are Ipca Laboratories Ltd., Zydus Group, Merck KGaA, Pfizer Inc., GSK plc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Alvizia Health Care, Bayer AG, and F. Hoffmann-La Roche Ltd.
  • Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global anti-malarial drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-malarial drugs market

Detailed Segmentation:

  • Global Anti-malarial Drugs Market, By Drug Class:
    • Aminoquinolines
    • Quinoline-methanol (4-quinolinemethanols)
    • Cinchona Alkaloids
    • Biguanides
    • Sulfonamides and sulfones
    • Others
  • Global Anti-malarial Drugs Market By Route of Administration:
    • Oral
    • Injectable
  • Global Anti-malarial Drugs Market By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Anti-malarial Drugs Market, By Region:
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Ipca Laboratories Ltd.
    • Zydus Group
    • Merck KGaA
    • Pfizer Inc.
    • GSK plc.
    • Cipla Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Novartis AG
    • Alvizia Health Care
    • Bayer AG
    • Hoffmann-La Roche Ltd

 “*” marked represents similar segmentation in other categories in the respective section

Detailed Segmentation:

  • Global Anti-malarial Drugs Market, By Drug Class:
    • Aminoquinolines
    • Quinoline-methanol (4-quinolinemethanols)
    • Cinchona Alkaloids
    • Biguanides
    • Sulfonamides and sulfones
    • Others
  • Global Anti-malarial Drugs Market By Route of Administration:
    • Oral
    • Injectable
  • Global Anti-malarial Drugs Market By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Anti-malarial Drugs Market, By Region:
    • North America
      • By Drug Class:
        • Aminoquinolines
        • Quinoline-methanol (4-quinolinemethanols)
        • Cinchona Alkaloids
        • Biguanides
        • Sulfonamides and sulfones
        • Others
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Class:
        • Aminoquinolines
        • Quinoline-methanol (4-quinolinemethanols)
        • Cinchona Alkaloids
        • Biguanides
        • Sulfonamides and sulfones
        • Others
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class:
        • Aminoquinolines
        • Quinoline-methanol (4-quinolinemethanols)
        • Cinchona Alkaloids
        • Biguanides
        • Sulfonamides and sulfones
        • Others
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class:
        • Aminoquinolines
        • Quinoline-methanol (4-quinolinemethanols)
        • Cinchona Alkaloids
        • Biguanides
        • Sulfonamides and sulfones
        • Others
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class:
        • Aminoquinolines
        • Quinoline-methanol (4-quinolinemethanols)
        • Cinchona Alkaloids
        • Biguanides
        • Sulfonamides and sulfones
        • Others
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class:
        • Aminoquinolines
        • Quinoline-methanol (4-quinolinemethanols)
        • Cinchona Alkaloids
        • Biguanides
        • Sulfonamides and sulfones
        • Others
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.